S&P Global vs J&J — Even Wide Moats Need the Right Price
S&P Global vs J&J — Even Wide Moats Need the Right Price
TL;DR S&P Global trades near fair value with a declining ROIC that warrants caution, while Johnson & Johnson sits 32% above Morningstar's price target despite solid fundamentals. Both have wide moats — but only one has the price to match.
Two companies. Both with moats deep enough that competitors rarely bother trying. Yet one shows up on the "buy" list and the other on the "sell" list.
S&P Global (SPGI) and Johnson & Johnson (JNJ) recently landed on opposite sides of analyst recommendations from Morningstar and Forbes. Here's what the numbers actually say when you run them through a proper valuation process.
S&P Global — A Regulatory Fortress at a Price
S&P Global is a $130 billion market cap business. It runs the S&P 500 index, operates one of only two nationally recognized credit rating agencies worldwide, owns commodity pricing benchmarks, and sells market intelligence data to institutional investors globally.
The moat here is regulatory. Which rating agencies get accepted doesn't change overnight — it almost never changes at all. The S&P 500 index benchmarks trillions of dollars in ETFs and funds. That's not going anywhere.
Morningstar's Dave Sakara sees a 21% discount to fair value. The stock got dragged down alongside names investors thought were vulnerable to AI disruption. Sakara pushes back hard: AI makes proprietary data more valuable, not less.
The numbers:
- Enterprise value: $152 billion ($23 billion in net debt above market cap)
- Free cash flow: $4 billion 5-year average, $5.5 billion last year
- P/FCF: 24x, P/E: 29x
- Operating margin: 29% — stable across 1-year, 5-year, and 10-year averages
- PEG ratio: 3.33 — meaningfully above growth rate
- Revenue growth: 11% annually for both 3 and 10 years, largely organic
One concern stands out. Return on invested capital has been falling: 37% over 10 years, 16.87% over 5 years, 7.5% last year. That trajectory matters. A business that handles invested capital less efficiently over time is a business getting structurally worse at compounding.
My 10-year analysis assumptions: 3–7% revenue growth, 33–35% FCF margin, 14–22x terminal P/FCF, 9% required return. Result: low $245, mid $340, high $470. At $425, it's not in my buy zone.
Johnson & Johnson — The Defensive Trap
JNJ is a $600 billion colossus. Pharmaceuticals, MedTech, one of the most recognizable healthcare brands on earth. It traded around $140 for years before running up significantly.
Morningstar rates it a sell at 32% above their price target. The stock rallied as investors piled into "defensive" names during market volatility. That's a sentiment premium, not a fundamental one.
- Free cash flow: ~$20 billion annually (below net income due to pharma R&D reinvestment)
- PEG ratio: 1.48 — much more reasonable than SPGI's 3.33
- Operating margin: trending up — 21.5% (10-year) → 26% (5-year) → 28.5% (last year)
- Dividend yield: 2%, consuming $12 billion of $19 billion in FCF
- High gross margins, decent growth for a mega-cap
The issue is purely price. Five-year P/E and P/FCF are both at historically elevated levels.
My assumptions: 2–4% revenue growth, 19–24% FCF margin, 16–22x terminal P/E, 9% required return. Result: low $108, mid $150, high $195. Against the current stock price, that's clearly overvalued.
Head to Head
| Metric | S&P Global (SPGI) | Johnson & Johnson (JNJ) |
|---|---|---|
| Market cap | $130B | $600B |
| Moat type | Regulatory (ratings, index monopoly) | Brand + patent |
| PEG ratio | 3.33 | 1.48 |
| Margin trend | Stable (29%) | Rising (21→28%) |
| ROIC trend | Declining (37%→7.5%) | Stable |
| Mid fair value | $340 | $150 |
| Current price | $425 | 32% above fair value |
| Verdict | Good business, still pricey | Great business, clearly overpriced |
Here's what's counterintuitive: JNJ's PEG at 1.48 looks far cheaper than SPGI's 3.33, but JNJ is actually more overvalued relative to intrinsic worth. One ratio never tells the full story.
The Real Lesson
Both companies will exist in 20 years. Both will earn more than they do today. But a great company and a great investment are not the same thing. The price you pay determines everything.
In a market rattled by geopolitical conflict and oil price spikes, the instinct to buy "safe" stocks is understandable. But buying a safe business at an unsafe price is still a bad investment. Discipline on valuation is what separates investors from speculators — especially when the noise is loudest.
Next Posts
Amazon's $132 Billion Capex — What Ugly Financials Are Hiding
Amazon's $132 Billion Capex — What Ugly Financials Are Hiding
Amazon's free cash flow is $7.7 billion against $77 billion in net income. The $132 billion capex gap isn't a problem — it's a signal of future investment. Mid-case fair value sits at $234 vs current price of $209.
Broadcom vs Apple — The AI Infrastructure Winner and the Overvaluation Debate
Broadcom vs Apple — The AI Infrastructure Winner and the Overvaluation Debate
Broadcom trades at 60x P/FCF but 35% revenue growth justifies the multiple. Apple looks cheaper at 30x but 5-7% growth makes it harder to sustain. Fair values: AVGO $355 (current $325), AAPL $200 (current $253).
S&P 500 Closes Below the 200-Day Moving Average — First Bearish Signal in a Year
S&P 500 Closes Below the 200-Day Moving Average — First Bearish Signal in a Year
The S&P 500, SPY, QQQ, and NASDAQ all closed below their 200-day moving averages on Friday — the first time in roughly a year. Oil-driven inflation combined with zero rate cut expectations for 2026 triggered VIX spikes and margin call cascades across asset classes.
Previous Posts
International Index Funds: The Portfolio Edge Most Investors Overlook
International Index Funds: The Portfolio Edge Most Investors Overlook
With US stock valuations at historic highs, international developed market index funds are becoming essential. Fidelity's FSPSX left Schwab's SWISX behind by $482,000 over 30 years. Here's why global diversification is a necessity, not a luxury.
The Compounding Power of Zero-Fee Index Funds: Why 0.02% Costs More Than You Think
The Compounding Power of Zero-Fee Index Funds: Why 0.02% Costs More Than You Think
The difference between a 0.02% and 0% expense ratio is just $20 per year on $100,000. But over 30 years of compounding, it contributes to a gap exceeding $1 million in total market funds alone. Here's why Fidelity's zero-fee strategy is a structural advantage.
S&P 500 Surges on Iran Strike Delay — Dead Cat Bounce or Genuine Bottom?
S&P 500 Surges on Iran Strike Delay — Dead Cat Bounce or Genuine Bottom?
The S&P 500 rallied back to its 200-day moving average after Trump delayed strikes on Iranian power plants, but Iran denying any dialogue and the 50% Fibonacci retracement overhead suggest it is too early to call a bottom. The 8.2% peak-to-trough correction may have further to run.